New/Revised Entities in Gastrointestinal Lymphoproliferative Disorders

Jassim, Sarmad; Smith, Lauren B.

doi:10.1016/j.path.2019.03.011

Cited by 2 publications

(2 citation statements)

References 86 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…TIA-1 is expressed in most CD4− cases, both CD8− and CD8+ (75% and 83%, respectively), and in three out of four tested cases with subsequent transformation to high-grade lymphoma (the three of them being CD4−/CD8+). Positivity for granzyme B is far lower in both groups, and negativity for both cytotoxic markers has been reported in all CD4+ cases [ 12 , 13 , 17 , 26 , 28 , 36 ]. These findings highlight the striking similarities between CD8+ iTLPD-GIs and indolent CD8+ lymphoid proliferations of the ear/primary cutaneous acral CD8+ T-cell lymphomas, which affect mostly males [ 37 , 38 , 39 ].…”

Section: Immunophenotypical Profile Of Itlpd-gimentioning

confidence: 99%

“…The vast majority of patients have an indolent and protracted clinical course, lasting for years to decades, with persistent disease and/or occasional relapses (chronic relapsing clinical course) [ 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 26 ]; most iTLPD-GIs have limited or no response to conventional chemotherapy [ 3 , 6 , 7 , 10 , 11 , 12 , 14 , 15 , 16 , 24 , 25 ], and it has been suggested that localized forms may benefit from involved-field radiotherapy (IFRT) [ 27 ].…”

Section: Updated Clinical and Pathological Findings On Itlpd-gimentioning

confidence: 99%

See 1 more Smart Citation

Indolent T-Cell Lymphoproliferative Disorders of the Gastrointestinal Tract (iTLPD-GI): A Review

Sanguedolce

Zanelli

Zizzo

et al. 2021

Cancers

View full text Add to dashboard Cite

iTLPD-GI is a low-grade clonal T-cell lymphoproliferative disease arising in GI organs. It is an uncommon disease, and only recently has it been enlisted as a distinct provisional entity in the current WHO Classification. Data from the literature disclose high heterogeneity in terms of pathological and molecular features; on the other hand, establishing an accurate diagnosis of iTLPD-GI is of pivotal importance, since treatment options are different from that of other, more frequent lymphomas that arise in the gastrointestinal tract. In this review, we aimed to better define this novel entity, and to identify useful diagnostic biomarkers; moreover, we provide a biomarker-based approach to the diagnosis and describe the most common issues in differentiating iTLPD-GI from other neoplastic and non-neoplastic disorders.

show abstract